Titan Pharmaceuticals
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
400 Oyster Point Blvd Ste 505, South San...Phone Number
(650) 244-4990Website
www.titanpharm.comRevenue
<$5 MillionStock Symbol
TTNPIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.Explore more
Titan Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Titan Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Titan Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when Titan Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Titan Pharmaceuticals recently announced quarterly report
Titan Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Titan Pharmaceuticals
Funding: Get notified immidiatlly once Titan Pharmaceuticals has new funding data
Check out if Titan Pharmaceuticals is spiking on competitors!
Check if Titan Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Titan Pharmaceuticals
Compare insights from companies similar to Titan Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Titan Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Titan Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Titan Pharmaceuticals.
Titan Pharmaceuticals financials insights
Gather financial insights about Titan Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2009
Debt
$3M
2010
Debt
$5M
2017
Debt
$10M
2020
Debt
$350K
2022
Share Placement
$5.5M
Titan Pharmaceuticals Tech Stack
A closer look at the technologies used by Titan Pharmaceuticals
Most Recent Scoops
Earnings
Titan Pharmaceuticals has recently released 2020 Q3 report with the following insight: Lack of funding and reliance on grants/investors creates uncertainty. Will require future dilutive financing or partnerships to advance clinically. Organizational turbulence with recent departures like CEO.
Earnings
Titan Pharmaceuticals has recently released 2020 Q3 report with the following insight: Titan Pharmaceuticals is pivoting to focus on two key assets that could drive future growth: JT-09 for treatment of chronic pruritus, and a nalmefene implant for prevention of opioid relapse. The JT-09 program leverages Titan ProNeura long-term drug delivery platform and aims to provide sustained delivery of a kappa opioid receptor agonist peptide for up to 6 months to treat debilitating chronic itch conditions. The nalmefene implant also utilizes ProNeura to provide long-term prevention of opioid relapse following detoxification. Titan believes these assets have significant commercial potential.
Earnings
Titan Pharmaceuticals has recently released 2020 Q3 report with the following insight: Competition from bigger players, especially on JT-09 where late-stage assets like Cara exist. Regulatory risks around securing first approvals for long-acting drugs. Market adoption/reimbursement uncertainties as with any novel therapeutic.
Earnings
Titan Pharmaceuticals has recently released 2020 Q3 report with the following insight: Experienced leadership team with drug development expertise. ProNeura sustained delivery platform provides competitive differentiation. NIH grant funding and NIDA support validate nalmefene program potential.
Earnings
Titan Pharmaceuticals News & Media
Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.
NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) announced today the filing by Black Titan Corporation with the U.S. Securities and Exchange Commission (“SEC”) of a registration statement on Form F-4 in connection with the proposed combination of Titan and TalenTec Sdn. Bhd. (f/k/a KE Sdn. Bhd.) (“TalenTec”), which includes Titan’s preliminary proxy statement (the “Form F-4”)Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock
NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities purchase agreement (the “Purchase Agreement”) with Blue Harbour Asset Management L.L.C-FZ (“Blue Harbour”), it has completed a private placement of the Company’s newly designated Series B Convertible Preferred Stock (the “Preferred Stock”). Pursuant to the Purchase Agreement, Blue Harbour purchased 100,000 shares of Preferred Stock forTitan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today reported that it received a notice (the “5250 Notice”) on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (“Rule 5250”) as a result of its failure to file its Quarterly Report on FormTitan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the “Merger Agreement”) regarding a business combination with KE Sdn. Bhd. (“KE”). The Merger Agreement was approved by Titan’s board of directors (the “Board”). If the Merger Agreement is approved by the stockholders of Titan and KE (and the other closing conditions are satisfied or waived
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Titan Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining... Read More
